https://www.spandidos-publications.com/or/37/1/57 'In...

https://www.spandidos-publications.com/or/37/1/57
  


'In conclusion, 90Y radioembolization is an effective treat-
ment for CRCLM in extending local control for liver dominant
metastatic disease. However, KRAS mutant tumors may be
more radio-resistant to treatment. In this study, changes in
ccfDNA FI were correlated with overall survival, likely indi-
cating that these changes are reflective of treatment response.
Measurements of FI may have the potential to be another
molecular biomarker that could predict treatment response to
therapy.'

Yttrium-90 radioembolization for colorectal cancer liver metastases in KRAS wild-type and mutant patients: